Current role of gemcitabine in the treatment of Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 49, Issue 5, 2008, Pages 883-889

  Oki, Yasuhiro ^a   Younes, Anas ^b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chemotherapeutic approaches; Drug resistance; Lymphoma and Hodgkin disease; Neoplasia

Indexed keywords

ANTICOAGULANT AGENT; BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEOXYCYTIDINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; METHYLPREDNISOLONE; NAVELBINE; OXALIPLATIN; PREDNISOLONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; STEROID; VINBLASTINE; VINCRISTINE;

ALOPECIA; ANEMIA; BLEEDING; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LETHARGY; LEUKOPENIA; LUNG INFILTRATE; LUNG TOXICITY; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OPTIMAL DRUG DOSE; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; SIDE EFFECT; STEM CELL TRANSPLANTATION; THORAX RADIOGRAPHY; THROMBOCYTE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; HODGKIN DISEASE; HUMANS; TREATMENT OUTCOME;

EID: 46749090038     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190801911704     Document Type: Review

References (31)

1. Horning, S. J. (2007) Risk, cure and complications in advanced Hodgkin disease. ASH Educ Prog, 2007, pp. 197-203.
2. Linch, D. C., Winfield, D., Goldstone, A. H., Moir, D., Hancock, B. and McMillan, A. (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet, 341, pp. 1051-1054.
3. Armitage, J. O., Bierman, P. J., Vose, J. M., Anderson, J. R., Weisenburger, D. D. and Kessinger, A. (1991) Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. Am J Med, 91, pp. 605-611.
4. Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A. M. and Haenel, M. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet, 359, pp. 2065-2071.
5. Aparicio, J., Segura, A., Garcera, S., Oltra, A., Santaballa, A. and Yuste, A. (1999) ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol, 10, pp. 593-595.
6. Ferme, C., Bastion, Y., Lepage, E., Berger, F., Brice, P. and Morel, P. (1995) The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Ann Oncol, 6, pp. 543-549.
7. Pfreundschuh, M. G., Rueffer, U., Lathan, B., Schmitz, N., Brosteanu, O. and Hasenclever, D. (1994) Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin's Disease Study Group. J Clin Oncol, 12, pp. 580-586.
8. Colwill, R., Crump, M., Couture, F., Danish, R., Stewart, A. K. and Sutton, D. M. (1995) Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol, 13, pp. 396-402.
9. Plunkett, W., Huang, P., Searcy, C. E. and Gandhi, V. (1996) Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol, 23, pp. 3-15.
10. Santoro, A., Bredenfeld, H., Devizzi, L., Tesch, H., Bonfante, V. and Viviani, S. (2000) Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study. J Clin Oncol, 18, pp. 2615-2619.
11. Venkatesh, H., Di Bella, N, Flynn, T. P., Vellek, M. J., Boehm, K. A. and Asmar, L. (2004) Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma, 5, pp. 110-115.
12. Zinzani, P. L., Bendandi, M., Stefoni, V., Albertini, P., Gherlinzoni, F. and Tani, M. (2000) Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica, 85, pp. 926-929.
13. Baetz, T., Belch, A., Couban, S., Imrie, K., Yau, J. and Myers, R. (2003) Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: A phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol, 14, pp. 1762-1767.
14. Kuruvilla, J., Nagy, T., Pintilie, M., Tsang, R., Keating, A. and Crump, M. (2006) Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma. Cancer, 106, pp. 353-360.
15. Ng, M., Waters, J., Cunningham, D., Chau, I., Horwich, A. and Hill, M. (2005) Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer, 92, pp. 1352-1357.
16. Bartlett, N., Niedzwiecki, D., Johnson, J., Friedberg, J., Johnson, K. and van Besien, K. (2007) Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol, 18, pp. 1071-1079.
17. Santoro, A., Magagnoli, M., Spina, M., Pinotti, G., Siracusano, L. and Michieli, M. (2007) Ifosfamide, gemcitabine, and vinorelbine: A new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica, 92, pp. 35-41.
18. Younes, A., Romaguera, J., Hagemeister, F., McLaughlin, P., Rodriguez, M. A. and Fiumara, P. (2003) A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer, 98, pp. 310-314.
19. Jones, R. J., Lin, L., Gocke, C., Hensley, K., Siedner, M. and Barber, J. P. (2006) Clonotypic B cells circulate in Hodgkin's lymphoma (HL). Blood, 108, p. 470a.
20. Younes, A., Fayad, L. Y., Goy, A., McLaughlin, P., Pro, B. and Romaguera, J. (2006) Results of rituximab plus ABVD in 65 newly diagnosed patients with classical Hodgkin lymphoma: Improvement of event free survival in all international prognostic score groups. Blood, 108, p. 2742a.
21. Oki, Y., Pro, B., Fayad, L. E., Romaguera, J., Samaniego, F. and Hagemeister, F. (2008) Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer, 112, pp. 831-836.
22. Friedberg, J. W., Kelly, J., Voci, S., Marquis, D., Rich, L. and Rossi, R. (2007) Bortezomib and Gemcitabine in Relapsed Hodgkin Lymphoma (HL). Blood, 110, p. 2325a.
23. Arai, S., Negrin, R., Blume, K., Johnston, L., Laport, G. and Lowsky, R. (2005) A phase I trial with extended cohort of gemcitabine and vinorelbine followed by autologous peripheral blood stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. J Clin Oncol, 23, p. 6651a.
24. Smardova, L., Engert, A., Haverkamp, H., Raemakers, J., Baars, J. and Pfistner, B. (2005) Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease. Leuk Lymphoma, 46, pp. 1017-1022.
25. Moskowitz, C. H., Kewalramani, T., Nimer, S. D., Gonzalez, M., Zelenetz, A. D. and Yahalom, J. (2004) Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol, 124, pp. 645-652.
26. Akhtar, S., Tbakhi, A., Humaidan, H., El Weshi, A, Rahal, M. and Maghfoor, I. (2006) ESHAP + fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: A single institution result of 127 patients. Bone Marrow Transplant, 37, pp. 277-282.
27. Magagnoli, M., Spina, M., Balzarotti, M., Timofeeva, I., Isa, L. and Michieli, M. (2007) IGEV regimen and a fixed dose of lenograstim: An effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant, 40, pp. 1019-1025.
28. Friedberg, J. W., Neuberg, D., Kim, H., Miyata, S., McCauley, M. and Fisher, D. C. (2003) Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: Unacceptable acute pulmonary toxicity. Cancer, 98, pp. 978-982.
29. Bredenfeld, H., Franklin, J., Nogova, L., Josting, A., Fries, S. and Mailander, V. (2004) Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: A report of the German Hodgkin's Lymphoma Study Group. J Clin Oncol, 22, pp. 2424-2429.
30. Belknap, S. M., Slimack, N., Kuzel, T., Carson, K. R., Yarnold, P. R. and Raisch, D. W. (2004) Severe gemcitabine-associated lung injury in Hodgkin's disease and other cancers: Reporting quality and clinical characteristics of cases reported in the medical literature and to the FDA. Blood, 104, p. 3145a.
31. Straus, D., LaCase, A., Juweid, M., Kostakogolu, L., Hall, N. and Johnson, J. (2007) Doxorubicin, vinblastine and gemcitabine (AVG), a novel regimen excluding bleomycin for the treatment of early stage Hodgkin lymphoma (HL): Results of CALGB 50203. Blood, 110, p. 214a.